Phosphodiesterase 4 regulates the migration of B16-F10 melanoma cells

Watanabe,Yoshihiro; Murata,Taku; Shimizu,Kasumi; Morita,Hiroshi; Inui,Madoka; Tagawa,Toshiro

doi:10.3892/etm.2012.587

Phosphodiesterase 4 regulates the migration of B16-F10 melanoma cells

Authors:
- Yoshihiro Watanabe
- Taku Murata
- Kasumi Shimizu
- Hiroshi Morita
- Madoka Inui
- Toshiro Tagawa
View Affiliations

Affiliations: Department of Oral and Maxillofacial Surgery, Division of Reparative and Regenerative Medicine, Institute of Medical Science, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan
Published online on: May 23, 2012 https://doi.org/10.3892/etm.2012.587
Pages: 205-210

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Phosphodiesterases (PDEs) are important regulators of signal transduction processes. Eleven PDE gene families (PDE1-11) have been identified and several PDE isoforms are selectively expressed in various cell types. PDE4 family members specifically hydrolyze cyclic AMP (cAMP). Four genes (PDE4A-D) are known to encode PDE4 enzymes, with additional diversity generated by the use of alternative mRNA splicing and the use of different promoters. While PDE4 selective inhibitors show therapeutic potential for treating major diseases such as asthma and chronic obstructive pulmonary disease, little is known concerning the role of PDE4 in malignant melanoma. In this study, we examined the role of PDE4 in mouse B16-F10 melanoma cells. In these cells, PDE4 activity was found to be ~60% of total PDE activity. RT-PCR detected only PDE4B and PDE4D mRNA. Cell growth was inhibited by the cAMP analog, 8-bromo-cAMP, but not by the specific PDE4 inhibitors, rolipram and denbufylline, which increased intracellular cAMP concentrations. Finally, migration of the B16-F10 cells was inhibited by the PDE4 inhibitors and 8-bromo-cAMP, while migration was increased by a protein kinase A (PKA) inhibitor, PKI14-22, and was not affected by 8-pCPT-2'-O-Me-cAMP, which is an analog of exchange protein activated by cAMP (Epac). The inhibitory effect of rolipram on migration was reversed by PKI14-22. Based on these results, PDE4 appears to play an important role in the migration of B16-F10 cells, and therefore may be a novel target for the treatment of malignant melanoma.

View Figures

View References

1.	Thompson JF, Scolyer RA and Kefford RF: Cutaneous melanoma. Lancet. 36:687–701. 2005. View Article : Google Scholar
2.	Eggermont AM and Robert C: New drugs in melanoma: it’s a whole new world. Eur J Cancer. 47:2150–2157. 2011.
3.	Beavo JA, Houslay MD and Francis SH: Cyclic nucleotide phosphodiesterase superfamily. Cyclic Nucleotide Phosphodiesterases In Health and Disease. Beavo JA, Francis SH and Hously MD: CRC Press; New York: pp. 3–17. 2007
4.	Hously MD, Schafer P and Zhang KY: Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today. 10:1503–1519. 2005. View Article : Google Scholar : PubMed/NCBI
5.	Hously MD: Underpinning compartmentalized cAMP signaling through targeted cAMP breakdown. Trends Biochem Sci. 35:91–100. 2010. View Article : Google Scholar : PubMed/NCBI
6.	Bolger GB, Conti M and Houslay MD: Cellular function of PDE4 enzymes. Cyclic Nucleotide Phosphodiesterases In Health and Disease. Beavo JA, Francis SH and Hously MD: CRC Press; New York: pp. 99–129. 2007
7.	Kim DH and Lerner A: Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia. Blood. 92:2484–2494. 1998.PubMed/NCBI
8.	Serrels B, Sandilands E, Serrels A, et al: A complex between FAK, RACK1, and PDE4D5 controls spreading initiation and cancer cell polarity. Curr Biol. 20:1086–1092. 2010. View Article : Google Scholar : PubMed/NCBI
9.	Fidler IJ: Selection of successive tumour lines for metastasis. Nat New Biol. 242:148–149. 1973. View Article : Google Scholar : PubMed/NCBI
10.	Murata T, Taira M and Manganiello VC: Differential expression of cGMP-inhibited cyclic nucleotide phosphodiesterases in human hepatoma cell lines. FEBS Lett. 390:29–33. 1996. View Article : Google Scholar : PubMed/NCBI
11.	Houslay MD, Sullivan M and Bolger GB: The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. Adv Pharmacol. 44:225–342. 1998. View Article : Google Scholar
12.	Moutasim KA, Nystrom ML and Thomas GJ: Cell migration and invasion assays. Methods Mol Biol. 731:333–343. 2011. View Article : Google Scholar : PubMed/NCBI
13.	Holz GG, Chepumy OG and Schwede F: Epac-selective cAMP analogs: new tools with which to evaluate the signal transduction properties of cAMP-regulated guanine nucleotide exchange factors. Cell Signal. 20:10–20. 2008. View Article : Google Scholar : PubMed/NCBI
14.	Davies SP, Reddy H, Caivano M and Cohen P: Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 351:95–105. 2000. View Article : Google Scholar : PubMed/NCBI
15.	Houslay MD: Hard times for oncogenic BRAF-expressing melanoma cells. Cancer Cell. 19:3–4. 2011. View Article : Google Scholar : PubMed/NCBI
16.	Marquette A, André J, Bagot M, Bensussan A and Dumaz N: ERK and PDE4 cooperate to induce RAF isoform switching in melanoma. Nat Struct Mol Biol. 18:584–591. 2011. View Article : Google Scholar : PubMed/NCBI
17.	Lau E and Ronai Z: RAF-isotype switching: from B to C through PDE. Nat Struct Mol Biol. 18:517–518. 2011. View Article : Google Scholar : PubMed/NCBI
18.	Dua P and Gude RP: Antiproliferative and antiproteolytic activity of pentoxifylline in cultures of B16F10 melanoma cells. Cancer Chemother Pharmacol. 58:195–202. 2006. View Article : Google Scholar : PubMed/NCBI
19.	Blackman BE, Horner K, Heidmann J, et al: PDE4D and PDE4B function in distinct subcellular compartments in mouse embryonic fibroblasts. J Biol Chem. 286:12590–12601. 2011. View Article : Google Scholar : PubMed/NCBI
20.	Abusnina A, Keravis T, Yougbare I, Bronner C and Lugnier C: Anti-proliferative effect of curcumin on melanoma cells is mediated by PDE1A inhibition that regulates the epigenetic integrator UHRF1. Mol Nutr Food Res. 55:1677–1689. 2011. View Article : Google Scholar : PubMed/NCBI
21.	Dua P and Gude RP: Pentoxifylline impedes migration in B16F10 melanoma by modulating Rho GTPase activity and actin organisation. Eur J Cancer. 44:1587–1595. 2008. View Article : Google Scholar : PubMed/NCBI
22.	Fleming YM, Frame MC and Houslay MD: PDE4-regulated cAMP degradation controls the assembly of integrin-dependent actin adhesion structures and REF52 cell migration. J Cell Sci. 117:2377–2388. 2004. View Article : Google Scholar : PubMed/NCBI